All Medical News
14 publications found
FDA Approves SIMTRIYO (centanafadine) as a Novel Non-Stimulant Treatment for ADHD
In July 2026, the FDA approved SIMTRIYO, a groundbreaking extended-release non-stimulant therapy modulating norepinephrine and dopamine to treat adult ADHD without abuse potential.
DEA Previews Final Permanent Rulemaking Framework for Telehealth Prescribing
In April 2026, the DEA unveiled its final draft establishing special telemedicine registration options bypassing in-person requirements for psychiatric care.
FDA Approves New Non-Addictive Antagonist for Chronic Insomnia Management
In April 2026, the FDA approved a novel orexin receptor antagonist promoting physiological sleep without next-day grogginess or habit-forming risks.
FDA Grants Breakthrough Designation to Targeted Neuromodulation Protocols for OCD
In April 2026, the FDA recognized a clinical breakthrough in non-invasive neuromodulation protocols for severe OCD management.
CCHP Highlights Interstate Telehealth Licensing Compact Expansion Across Key States
In March 2026, the CCHP confirmed new states joining the interstate medical compact, facilitating cross-border psychiatric care without duplicate paperwork.
FDA Endorses Blood Biomarker Validation Guidelines for Objective PTSD Diagnosis
In March 2026, the FDA issued guidelines supporting molecular blood biomarkers to complement clinical interviews for objective PTSD diagnosis.
FDA Approves New Treatment Option for Schizophrenia and Bipolar Maintenance
In March 2026, an extended-release formulation was approved minimizing weight and glucose side effects for bipolar and schizophrenia patients.
American Psychiatric Association (APA) Releases Updated 2026 Telepsychiatry Practice Standards
In February 2026, the APA updated its clinical practice standards recommending telepsychiatry as first-line care for anxiety and mood disorders.
Florida Strengthens Insurance Coverage Parity Statutes for Remote Psychiatric Care
In February 2026, updated Florida state statutes took effect requiring commercial insurers to reimburse virtual psychiatric visits at full parity with office visits.
FDA Grants Priority Review to Fast-Acting Non-Benzodiazepine Compound for Panic Disorder
In February 2026, the FDA granted priority review to a compound relieving acute panic attacks within minutes without sedation or dependence risks.
FDA Updates Clinical Monitoring Protocols for Esketamine Protocols in Treatment-Resistant Depression
In January 2026, the FDA issued updated guidelines streamlining safe clinical monitoring protocols for intranasal esketamine in resistant depression.
Five U.S. States Enact Mandatory Telehealth Insurance Parity Laws at the Start of 2026
In January 2026, five additional states enacted laws requiring health insurers to reimburse virtual mental health visits at 100% of in-person rates.
FDA Releases New Assessment Guidelines for ADHD Transition from Adolescence to Adulthood
In January 2026, the FDA presented an updated clinical framework to diagnose and treat ADHD in young adults transitioning from school years.
DEA Releases National PDMP Integration Report for Safe Telehealth Prescribing
In January 2026, the DEA reported a 98% integration rate across state prescription monitoring databases, enhancing safety in telepsychiatry.